Ellman International, a Baird Capital Partners portfolio company, launches next-generation aesthetic skin tightening technology

Ellman International, Inc., a Baird Capital Partners portfolio company, announced May 18 that the Food and Drug Administration (FDA) has granted clearance to Pellevé™, a skin tightening system for the non-ablative treatment of mild to moderate facial wrinkles and rhytids for skin phototypes I-IV. The clearance was granted based on clinical data demonstrating that a single treatment with the high frequency radiowave device can safely and effectively tighten and improve the appearance of skin on the face through six months. For more information, please read Ellman International’s news release